Hospital
Cookeville Regional Medical Center
Cookeville Regional Medical Center was paid $17.12M by Medicaid between Jan 2018 and Dec 2024, across 138 billing codes. Its largest line is 99284, emergency room visit (serious) — 30% of everything it billed.
33Billing provider infoCOOKEVILLE REGIONAL MEDICAL CENTER
COOKEVILLE, TN 38501
COOKEVILLE, TN 38501
33aNPI1275531956assigned 07/07/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$17.12M
24GClaims617,112
24DCodes billed138
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Tennessee
Rank by total paid#15 of 71
Median peer was paid$6.96M
This provider vs. median2.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 106,885 | $3.03M | |
| 2019 | 100,494 | $2.99M | |
| 2020 | 75,953 | $2.41M | |
| 2021 | 95,664 | $2.96M | |
| 2022 | 83,449 | $2.32M | |
| 2023 | 90,392 | $2.04M | |
| 2024incomplete | 64,275 | $1.38M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 32,678 | 30,343 | $5.13M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 35,304 | 33,112 | $4.09M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.5% | 9,300 | 8,537 | $1.63M |
| G0378 | Hospital observation service, per hour | 5.6% | 5,526 | 4,184 | $960K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 4.1% | 8,713 | 4,645 | $708K |
| 41899 | Unlisted procedure, dentoalveolar structures | 3.2% | 1,273 | 1,227 | $540K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.6% | 961 | 865 | $443K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.1% | 14,587 | 12,116 | $357K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.6% | 4,141 | 980 | $266K |
| G0379 | Direct admission of patient for hospital observation care | 1.5% | 2,309 | 1,756 | $260K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 70,357 | 58,433 | $242K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.2% | 2,364 | 1,251 | $209K |
126 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.0% | 4,360 | $176K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 16,404 | $165K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,013 | $159K |
| 84484 | <1% | 18,758 | $145K | |
| 80051 | <1% | 47,240 | $115K | |
| 82565 | <1% | 47,239 | $114K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,045 | $111K |
| 82947 | <1% | 47,226 | $100K | |
| J0875 | Injection, dalbavancin, 5 mg | <1% | 46 | $99K |
| 77412 | <1% | 1,421 | $92K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 796 | $75K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,421 | $68K |
| 87400 | <1% | 16,853 | $64K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 18,535 | $61K |
| 83605 | <1% | 11,406 | $57K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 8,209 | $49K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,993 | $42K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,275 | $33K |
| 71045 | Radiologic examination, chest; single view | <1% | 15,934 | $32K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 353 | $31K |
| 29581 | <1% | 1,684 | $30K | |
| 84703 | <1% | 5,506 | $28K | |
| 77336 | <1% | 685 | $24K | |
| 84520 | <1% | 12,962 | $23K | |
| 80076 | <1% | 9,796 | $22K | |
| 85730 | <1% | 9,727 | $21K | |
| 83690 | <1% | 5,581 | $20K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,546 | $20K |
| 80053 | Comprehensive metabolic panel | <1% | 8,836 | $17K |
| 85610 | <1% | 12,036 | $16K | |
| 80306 | <1% | 3,831 | $16K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 50 | $16K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 758 | $16K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 144 | $16K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,302 | $13K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 505 | $13K |
| 87807 | <1% | 1,923 | $12K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,398 | $11K |
| 81001 | <1% | 20,649 | $11K | |
| 87070 | <1% | 2,112 | $10K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 863 | $10K |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,238 | $10K |
| 11045 | <1% | 387 | $9K | |
| 83880 | <1% | 1,214 | $8K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 304 | $8K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 45 | $7K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 14 | $6K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,276 | $6K |
| 95811 | <1% | 27 | $6K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 83 | $5K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 14 | $5K |
| 80179 | <1% | 1,139 | $5K | |
| 80143 | <1% | 1,127 | $5K | |
| 87040 | <1% | 916 | $5K | |
| 81003 | <1% | 5,096 | $4K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 825 | $4K |
| 77334 | <1% | 19 | $4K | |
| 85378 | <1% | 758 | $3K | |
| 96367 | <1% | 90 | $3K | |
| 83874 | <1% | 854 | $3K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 28 | $3K |
| 76536 | <1% | 66 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,128 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 376 | $2K |
| 97597 | <1% | 32 | $2K | |
| 77290 | <1% | 13 | $2K | |
| 87631 | <1% | 16 | $1K | |
| 85027 | <1% | 735 | $1K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 30 | $1K |
| 82553 | <1% | 824 | $869.40 | |
| 83735 | <1% | 840 | $843.46 | |
| 77307 | <1% | 13 | $833.83 | |
| 96376 | <1% | 231 | $747.50 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 32 | $734.77 |
| 86140 | <1% | 187 | $575.55 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,945 | $461.28 |
| 84112 | <1% | 13 | $435.95 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 236 | $330.00 |
| 93925 | <1% | 15 | $264.66 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 416 | $256.42 |
| 82803 | <1% | 57 | $237.69 | |
| 80061 | Lipid panel | <1% | 53 | $231.09 |
| 84702 | <1% | 13 | $219.86 | |
| 82962 | <1% | 312 | $205.26 | |
| 82310 | <1% | 79 | $195.94 | |
| 82607 | <1% | 14 | $142.44 | |
| 86038 | <1% | 14 | $142.07 | |
| 83704 | <1% | 27 | $139.50 | |
| 77417 | <1% | 89 | $119.82 | |
| 87186 | <1% | 17 | $111.93 | |
| 84439 | <1% | 31 | $111.72 | |
| 82550 | <1% | 15 | $95.64 | |
| 82728 | <1% | 13 | $95.10 | |
| 82172 | <1% | 43 | $94.13 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 66 | $93.82 |
| 76937 | <1% | 59 | $84.90 | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,850 | $79.32 |
| 86141 | <1% | 42 | $78.61 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 13 | $78.57 |
| 82248 | <1% | 18 | $67.48 | |
| 82247 | <1% | 18 | $67.48 | |
| 83695 | <1% | 26 | $57.25 | |
| 83615 | <1% | 32 | $55.92 | |
| 87088 | <1% | 25 | $55.74 | |
| 73610 | <1% | 15 | $54.45 | |
| 86900 | <1% | 29 | $47.36 | |
| 86901 | <1% | 29 | $47.36 | |
| 85652 | <1% | 15 | $31.80 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 31 | $26.76 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 76 | $21.80 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,023 | $19.28 |
| 82009 | <1% | 14 | $18.32 | |
| 83550 | <1% | 13 | $16.71 | |
| 74018 | <1% | 27 | $15.78 | |
| 84460 | <1% | 13 | $14.07 | |
| 82077 | <1% | 28 | $14.03 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,585 | $6.21 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 0% | 14 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 87 | $0.00 |
| A9270 | Non-covered item or service | 0% | 1,071 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 120 | $0.00 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 0% | 32 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 270 | $0.00 |
| C1769 | Guide wire | 0% | 77 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 21 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 60 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKEY, MARILYN (CEO)
| Provider | Location | Paid |
|---|---|---|
| Cookeville Regional Medical Group, INC | Cookeville, TN | $1.82M |
| Cookeville Regional Medical Center | Cookeville, TN | $1.13M |
| CRMC Mso Sub 1, Incorporated | Cookeville, TN | $651K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.